ClinicalTrials.gg
RecruitingNCT03826524EpiDOSEUpdated Oct 2, 2026

Epinephrine Dose: Optimal Versus Standard Evaluation Trial

A Phase 4 interventional study of Epinephrine in Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest and Ventricular Fibrillation, sponsored by Unity Health Toronto. Recruiting at 9 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Unity Health Toronto · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Updated Oct 2, 2026Primary completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada — 4 open to participants now, 6 under way, none of them phase 3. Out-of-Hospital Cardiac Arrest · Canada.

Planned enrollment
3rd of 14
1,250 · median 397
Started
2023
the only one that year
Phase 4
2 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
1 of 16
Unity Health Toronto

Among the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 7th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

4 of the 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Out-of-Hospital Cardiac Arrest with a site in Canada, or all of them as a file.
02

Study summary

The objective of this randomized controlled trial is to evaluate whether a low cumulative dose of epinephrine ("low dose") is non-inferior to a standard cumulative dose of epinephrine ("standard dose") with respect to survival to hospital discharge among adults undergoing resuscitation for OHCA due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT).

Read the detailed description

This study is designed as a prospective, multicentre, single-blinded randomized controlled trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.

Eligible OHCA patients will be treated by paramedics who will initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per paramedic agencies' treatment protocols. After one defibrillation and when feasible, paramedics will establish peripheral intravenous (IV) access, and patients will be randomly allocated to either the low dose or standard dose treatment arm. Epinephrine doses (according to treatment assignment) will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, until the first return of spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. Follow-up will take place using a combination of administrative databases (e.g. the Discharge Abstract Database and the National Ambulatory Care Reporting System) and telephone interviews.

This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine. Please feel free to contact epidose@unityhealth.to for further information.

03

Conditions studied

  • Cardiac Arrest, Out-Of-Hospital
  • Sudden Cardiac Arrest
  • Ventricular Fibrillation
  • Ventricular Tachycardia-Pulseless

Keywords

  • out-of-hospital cardiac arrest
  • sudden cardiac arrest
  • epinephrine
  • randomized controlled trial
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Out-of-hospital cardiac arrest treated by paramedics AND
  • Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics or fire services, AND
  • Established intravenous vascular access

Exclusion criteria

Exclusion Criteria:

  • Known or apparent age \<18 years
  • Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics
  • Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
  • Administration of intramuscular, endotracheal tube, or intraosseous epinephrine
  • Prisoners or persons in police custody
  • Known allergy or sensitivity to epinephrine
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,250 participants (estimated)

Study arms

  • Active comparator
    Low Dose Epinephrine

    Epinephrine up to 2mg total

    Drug: Epinephrine

  • Active comparator
    Standard Dose Epinephrine

    Epinephrine up to 6mg total

    Drug: Epinephrine

Interventions

  • Epinephrine 1mg 1:10000 (10cc) per dose

    Also known as: Adrenaline

06

What researchers measure

Primary outcomes

  1. Survival to hospital discharge

    Individuals discharged alive from hospital

    Time frame: Through study completion (up to 5 years)

Secondary outcomes

  1. Return of spontaneous circulation in out-of-hospital setting

    Return of spontaneous circulation in the field

    Time frame: Through study completion (up to 5 years)

  2. Survival to emergency department arrival

    Individuals alive upon arrival to a hospital emergency department

    Time frame: Through study completion (up to 5 years)

  3. Survival to admission with death prior to discharge

    Individuals alive upon hospital admission who die in-hospital before being discharged

    Time frame: Through study completion (up to 5 years)

  4. Survival to discharge outside of a long-term healthcare facility e.g. nursing home

    Individuals discharged alive from hospital to a care facility

    Time frame: Through study completion (up to 5 years)

  5. Modified Rankin Scale (mRS) score

    Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead)

    Time frame: 12+/-3 months

  6. Health Utility Index-3 (HUI-3) score

    Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health)

    Time frame: 12+/-3 months

  7. Hospital Anxiety and Depression Scale score

    Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression

    Time frame: 12+/-3 months

  8. Length of stay in hospital

    Length of time an individual remained in-hospital (length in days)

    Time frame: Through study completion (up to 5 years)

  9. Length of stay in critical care unit

    Length of time an individual remained in a crucial care unit (length in days)

    Time frame: Through study completion (up to 5 years)

  10. Survival post-arrest

    Survival following hospital discharge, up to 5 years

    Time frame: Up to 5 years

  11. Recurrent cardiac arrest(s)

    Number of cardiac arrests following the index arrest

    Time frame: Up to 5 years

  12. ICD implant post-arrest

    Whether an implantable cardioverter defibrillator was implanted post-arrest

    Time frame: Up to 5 years

  13. Cardiovascular re-hospitalization(s)

    Number of cardiovascular re-hospitalizations

    Time frame: Up to 5 years

  14. All-cause re-hospitalizations(s)

    Number of re-hospitalizations for any reason

    Time frame: Up to 5 years

07

Study locations

9 of 9 sites recruiting
  • British Columbia Emergency Health Services (BCEHS)
    Victoria, British Columbia V8W 9P1, Canada
    Recruiting
  • Peel Regional Paramedic Services
    Brampton, Ontario L6T 4B9, Canada
    Recruiting
  • Middlesex-London Paramedic Service
    London, Ontario N6E 1R4, Canada
    Recruiting
    • Manya Charette · Contactmancharette@ohri.ca · 613-798-5555
    • Christian Vaillancourt, MD · Principal investigator
    • Matthew Davis, MD · Sub investigator
  • Halton Region Paramedic Services
    Oakville, Ontario L6M 3L1, Canada
    Recruiting
    • Theresa Aves · Contactepidose@unityhealth.to · 416-864-6060
    • Sheldon Cheskes, MD · Principal investigator
  • Ottawa Paramedic Services
    Ottawa, Ontario K1H 1E2, Canada
    Recruiting
    • Manya Charette · Contactmancharette@ohri.ca · 613-798-5555
    • Christian Vaillancourt, MD · Principal investigator
  • Superior North Emergency Medical Services
    Thunder Bay, Ontario P7B 4X6, Canada
    Recruiting
    • Manya Charette · Contactmancharette@ohri.ca · 613-798-5555
    • Christian Vaillancourt, MD · Principal investigator
    • David Savage, MD · Sub investigator
  • Region of Waterloo Paramedic Services
    Waterloo, Ontario N2G 4J3, Canada
    Recruiting
    • Kathy Winter, MD · Contactwinterkat@hhsc.ca · 905-521-2100
    • Paul Miller, MD · Principal investigator
  • Essex-Windsor Emergency Health Services
    Windsor, Ontario N9A 1N6, Canada
    Recruiting
    • Manya Charette · Contactmancharette@ohri.ca · 613-798-5555
    • Christian Vaillancourt, MD · Principal investigator
  • Medavie Health Services West
    Saskatoon, Saskatchewan S7J 4M2, Canada
    Recruiting
    • Tracy Wilson, PhD · Contacttracy.wilson@usask.ca · 306-655-2810
    • Andrew Leach, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2023 (actual). Primary completion is estimated for Dec 2028, 67 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2018
First posted
Feb 1, 2019
StartActual
May 24, 2023
Primary completionEst.
Dec 2028was Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Region of Waterloo Paramedic Services · Waterloo, Canada
Oct 2, 2026
Primary completion
Dec 2027→Dec 2028
Oct 2, 2026
Enrollment
3790→1250
Oct 2, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedOut-of-hospital cardiac arrest treated by paramedics AND
  • EditedInitial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessedconfirmed by EMS (paramedicparamedics or fire) services, AND
Oct 2, 2026
Sponsor
Collaborators removed: Pfizer
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    1 site added
    Show site
    • Region of Waterloo Paramedic Services · Waterloo, Canada
    Primary completion Dec 2027→Dec 2028
    Enrollment 3790→1250
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedOut-of-hospital cardiac arrest treated by paramedics AND
    • EditedInitial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessedconfirmed by EMS (paramedicparamedics or fire) services, AND
    Sponsor Collaborators removed: Pfizer
    + 2 other changes: identifiers and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03826524
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
May 24, 2023
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Theresa Aves, MSc
Contact
theresa.aves@unityhealth.to
416-864-6060 ext. 46787
Paul Dorian, MD, MSc
principal investigator · Unity Health Toronto
Steve Lin, MD, MSc
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epinephrine

Start the discussion